EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop, which is in Phase I safety study for multiple diseases that affect the ocular surface and anterior region of the eye, comprising of allergic conjunctivitis, viral conjunctivitis, and dry eye disease. The company also develops ocular bandage gel, a modified form of the natural polymer hyaluronic acid for corneal wound repair, and punctate epitheliopathies with a focus on dry eye. The company has license agreements with BioTime, Inc. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.
IPO Year: n/a
Exchange: NASDAQ
Website: eyegatepharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/16/2021 | $14.00 → $11.00 | Buy | HC Wainwright & Co. |
Lineup includes one Buffered product and four Fixed Income products in AB's ETF suite NASHVILLE, Tenn., Dec. 13, 2023 /PRNewswire/ -- AllianceBernstein Holding L.P. (NYSE:AB) and AllianceBernstein L.P., a leading global investment management and research firm, announced today the launch of five active exchange-traded funds (ETFs) on the NASDAQ and New York Stock Exchange (NYSE) Arca: AB Conservative Buffer ETF (NASDAQ:BUFC), AB Tax-Aware Intermediate Municipal ETF (NYSE:TAFM), AB Tax-Aware Long Municipal ETF (NYSE:TAFL), AB Corporate Bond ETF (NASDAQ:EYEG), and AB Core Plus Bond ETF (NASDAQ:CPLS). "On the heels of crossing the $1 billion threshold in active ETF AUM, these new ETFs will prov
SALT LAKE CITY, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), ("Kiora" or the "Company") is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG). Kiora will trade on the Nasdaq Capital Market under the ticker symbol "KPRX" and CUSIP number 49721T101. The new brand reflects the Company's aim to not only treat common eye conditions, but to develop a revolutionary small molecule therapy that has the potential to restore vision loss for a rare, inherited degenerative retinal disease, Retinitis Pigmentosa. The Company's newly revamped clinical development strategy is available in the Investors section of the Company's new website at www.kiorapharma.com. "T
WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that it has completed the planned acquisition of Bayon Therapeutics, Inc. ("Bayon") and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021. Dr. Daniels will drive ongoing development of EyeGate's pipeline of novel treatments for eye disease. This includes overseeing the development of a potential vision-restoring small molecule from Bayon, B-203, which acts as a ‘molecular p
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that EyeGate's President and Chief Executive Officer, Brian M. Strem, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021. The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7:00 a.m. ET on Monday, September 13, 2021. The presentation and archiv
-Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers- -Trial remains on track with topline data expected in Q4 2021- WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that it has completed target enrollment of 21 patients in the Phase 2 proof-of-concept ("POC") study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry e
WALTHAM, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today reported its financial results for the quarter ended June 30, 2021 and provided an update on recent corporate and operational activities. "In the second quarter of 2021 we made significant advancements to build our business and our clinical initiatives remain on track as we enter this new phase of continued growth," said Brian Strem, Ph.D., President and Chief Executive Officer of EyeGate. "We too
WALTHAM, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today announced the closing of its previously announced registered direct offering priced at-the-marked under Nasdaq rules of 4,668,844 shares of its common stock at a purchase price of $2.3025 per share for gross proceeds of approximately $10.75 million, before deducting placement agent's fees and other offering expenses. The Company also issued to the investors, in a concurrent private placement, unregi
WALTHAM, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale, in a registered direct offering priced at-the-marked under Nasdaq rules, of 4,668,844 shares of its common stock at a purchase price of $2.3025 per share for gross proceeds of approximately $10.75 million, before deducting placement agent's fees and other offering e
WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced that Brian M Strem, Ph.D., Co-Founder, Director and former Chief Executive Officer of Okogen, Inc as well as Co-Founder and Managing Director of Bayon Therapeutics, was appointed as permanent President, Chief Executive Officer and board member, effective immediately. He brings strategic expertise, scientific acumen and drug development experience in ophthalmology, otology and regenerative medicine t
- Proof-of-concept study conducted in Austria--Topline data expected in Q4 2021- WALTHAM, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today announced the first patient dosed in phase II proof-of-concept ("POC") study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye. PP-001, an immune-modulating molecule, is an inhibitor of dihydroorotate dehydrogenase ("DHODH") and
HC Wainwright & Co. reiterated coverage of Eyegate Pharmaceuticals with a rating of Buy and set a new price target of $11.00 from $14.00 previously
Alliance Global Partners reiterated coverage of EyeGate Pharmaceuticals with a rating of and set a new price target of $16.75 from $15.50 previously
SC 13G - EYEGATE PHARMACEUTICALS INC (0001372514) (Subject)
SC 13G - EYEGATE PHARMACEUTICALS INC (0001372514) (Subject)
SC 13G - EYEGATE PHARMACEUTICALS INC (0001372514) (Subject)
SC 13G - EYEGATE PHARMACEUTICALS INC (0001372514) (Subject)
SC 13G - EYEGATE PHARMACEUTICALS INC (0001372514) (Subject)
SC 13G - EYEGATE PHARMACEUTICALS INC (0001372514) (Subject)
SC 13D/A - EYEGATE PHARMACEUTICALS INC (0001372514) (Subject)
SC 13G/A - EYEGATE PHARMACEUTICALS INC (0001372514) (Subject)
4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
3 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
4 - EYEGATE PHARMACEUTICALS INC (0001372514) (Issuer)
4 - EYEGATE PHARMACEUTICALS INC (0001372514) (Issuer)
4 - EYEGATE PHARMACEUTICALS INC (0001372514) (Issuer)
4 - EYEGATE PHARMACEUTICALS INC (0001372514) (Issuer)
4 - EYEGATE PHARMACEUTICALS INC (0001372514) (Issuer)
4 - EYEGATE PHARMACEUTICALS INC (0001372514) (Issuer)
4 - EYEGATE PHARMACEUTICALS INC (0001372514) (Issuer)
4 - EYEGATE PHARMACEUTICALS INC (0001372514) (Issuer)
WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that it has completed the planned acquisition of Bayon Therapeutics, Inc. ("Bayon") and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021. Dr. Daniels will drive ongoing development of EyeGate's pipeline of novel treatments for eye disease. This includes overseeing the development of a potential vision-restoring small molecule from Bayon, B-203, which acts as a ‘molecular p
WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced that Brian M Strem, Ph.D., Co-Founder, Director and former Chief Executive Officer of Okogen, Inc as well as Co-Founder and Managing Director of Bayon Therapeutics, was appointed as permanent President, Chief Executive Officer and board member, effective immediately. He brings strategic expertise, scientific acumen and drug development experience in ophthalmology, otology and regenerative medicine t
WALTHAM, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory and immune diseases, today announced that it has appointed Kenneth Gayron and Aron Shapiro to the Company’s Board of Directors, effective immediately. Thomas Hancock, Morton Goldberg, M.D., and Bernard Malfroy-Camine, Ph.D., have stepped down from the board, which is now composed of seven members. Both Mr. Gayron and Mr. Shapiro bring a unique perspective, deep expertise and valuable insight to the Company. “We are very pleased to welcome these esteemed leaders to our board as we navigate our
Expands Pipeline Beyond Ophthalmology with PP-001, a Clinical Stage, Best-in-Class DHODH Inhibitor PP-001 Leverages a Validated Immune Modulating Mechanism Optimized for Increased Specificity and Picomolar Potency to Avoid Off-Target Side Effects Acquisition Strengthens Leadership Team with Appointment of Panoptes Co-Founders Dr. Franz Obermayr as EVP Clinical Development and Dr. Stefan Sperl as EVP CMC and Operations WALTHAM, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical stage company focused on developing products for treating disorders of the eye, today announced the acquisition of Panoptes Pharma (“Pano
10-Q - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
D - EYEGATE PHARMACEUTICALS INC (0001372514) (Filer)
8-K - EYEGATE PHARMACEUTICALS INC (0001372514) (Filer)
8-K - EYEGATE PHARMACEUTICALS INC (0001372514) (Filer)
8-K - EYEGATE PHARMACEUTICALS INC (0001372514) (Filer)
D - EYEGATE PHARMACEUTICALS INC (0001372514) (Filer)
10-Q - EYEGATE PHARMACEUTICALS INC (0001372514) (Filer)
424B5 - EYEGATE PHARMACEUTICALS INC (0001372514) (Filer)
8-K - EYEGATE PHARMACEUTICALS INC (0001372514) (Filer)